Article
Pharmacology & Pharmacy
Rui Xuan Huang, Damrongrat Siriwanna, William C. Cho, Tsz Kin Wan, Yan Rong Du, Adam N. Bennett, Qian Echo He, Jun Dong Liu, Xiao Tai Huang, Kei Hang Katie Chan
Summary: In this study, a pipeline based on machine learning was developed to predict potential target genes for LUAD and discover potential drugs for its treatment through drug repositioning. The pipeline achieved good predictive performance and identified several potential therapeutic drugs for LUAD.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Oncology
Seo Yun Kim, Eun-Hui Jeong, Tae-Gul Lee, Hye-Ryoun Kim, Cheol Hyeon Kim
Summary: Combining trametinib and temsirolimus reduced clonogenic survival and promoted radiation-induced apoptosis in lung cancer cells. Inhibition of MEK and mTOR together led to prolonged expression of gamma H2AX after irradiation and prolonged G(2)/M cell cycle arrest in A549 cells. In vivo studies showed that co-administration of the drugs increased lung cancer xenograft sensitivity to radiotherapy.
ANTICANCER RESEARCH
(2021)
Article
Medicine, Research & Experimental
Occam Kelly Graves, Woonghee Kim, Mehmet Ozcan, Sajda Ashraf, Hasan Turkez, Meng Yuan, Cheng Zhang, Adil Mardinoglu, Xiangyu Li
Summary: This study identified potential therapeutic target genes for lung adenocarcinoma and repurposed existing drugs. The effectiveness of these target genes and drugs was validated through in vitro experiments.
BIOMEDICINE & PHARMACOTHERAPY
(2023)
Article
Oncology
Sapna Oberoi, Amria Qumseya, Wei Xue, Douglas J. Harrison, Erin R. Rudzinski, Suzanne L. Wolden, Roshni Dasgupta, Rajkumar Venkatramani, Abha A. Gupta
Summary: This study aimed to determine the feasibility of incorporating temsirolimus into the standard COG chemotherapy regimen for intermediate-risk rhabdomyosarcoma. The results showed that weekly temsirolimus during VAC/VI chemotherapy was feasible and well tolerated. The efficacy of this regimen is currently being tested in a phase III randomized trial.
PEDIATRIC BLOOD & CANCER
(2023)
Article
Oncology
Sonia M. Abuzakhm, Vineeth Sukrithan, Briant Fruth, Rui Qin, Jonathan Strosberg, Timothy J. Hobday, Thomas Semrad, Diane Reidy-Lagunes, Hedy Lee Kindler, George P. Kim, Jennifer J. Knox, Andreas Kaubisch, Miguel Villalona-Calero, Helen Chen, Charles Erlichman, Manisha H. Shah
Summary: This study assessed the efficacy and safety of combining bevacizumab with temsirolimus for advanced extra-pancreatic neuroendocrine tumors. The results showed minimal efficacy and increased side effects with this combination therapy, and it is not recommended for use in these patients.
ENDOCRINE-RELATED CANCER
(2023)
Article
Oncology
Bob Meeusen, Emanuela Elsa Cortesi, Judit Domenech Omella, Anna Sablina, Juan-Jose Ventura, Veerle Janssens
Summary: This study found that the loss of PP2A activator PTPA in KRAS-mutant lung adenocarcinomas is associated with poorer overall survival, increased cell growth, and accelerated tumor formation. Additionally, the depletion of PPP2R4 induced resistance against MEK inhibitor but sensitized cells to mTOR inhibitor, highlighting its clinical relevance in NSCLC etiology and kinase inhibitor response.
Article
Genetics & Heredity
Lawrence Liu, Carina Dehner, Nikhil Grandhi, Yang Lyu, Dana C. Borcherding, John S. A. Chrisinger, Xiao Zhang, Jingqin Luo, Yu Tao, Amanda Parkes, Nam Q. Bui, Elizabeth J. Davis, Mohammed M. Milhem, Varun Monga, Mia Weiss, Brian Van Tine, Angela C. Hirbe
Summary: This study investigated the impact of genetic mutations in PEComa patients on treatment response, and found no significant association between gene mutations and survival rate or progression-free survival after treatment. Further research should focus on identifying other TSC-1/-2 silencing driver genes to predict response to mTOR inhibition therapy.
Review
Biochemistry & Molecular Biology
Eleni A. Karatrasoglou, Maria Dimou, Alexia Piperidou, Eleftheria Lakiotaki, Penelope Korkolopoulou, Theodoros P. Vassilakopoulos
Summary: This review focuses on discussing the oncogenic mechanisms of the PI3K/v-akt/mTOR pathway in B cell non-Hodgkin lymphoma (NHL), and summarizes the clinical applications of mTOR inhibitors in B cell NHLs.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Oncology
Guoshu Bi, Donglin Zhu, Yunyi Bian, Yiwei Huang, Cheng Zhan, Yong Yang, Qun Wang
Summary: Our study demonstrated that increased expression of GTF2E2 in LUAD tissue was negatively associated with patients' overall survival. Knocking down GTF2E2 inhibited LUAD cell proliferation, migration, invasion, promoted apoptosis in vitro, and attenuated tumor growth in vivo. Through LC-MS/MS analysis, we found that RPS4X may interact with GTF2E2 and mediate its regulatory effect on LUAD development through the mTOR pathway.
CANCER CELL INTERNATIONAL
(2021)
Article
Medicine, Research & Experimental
Guoyin Li, Zewen Song, Changjing Wu, XiaoYan Li, Liping Zhao, Binghua Tong, Zhenni Guo, Meiqing Sun, Jin Zhao, Huina Zhang, Lintao Jia, Shengqing Li, Lei Wang
Summary: Cumulative evidence suggests that abnormal regulation of the NEDD4 family is involved in tumorigenesis and cancer development. This study found that NEDD4L is associated with overall survival in lung adenocarcinoma (LUAD) patients and may regulate the mTORC1 pathway. Experimental results demonstrate that NEDD4L inhibits mTOR signaling activity and significantly inhibits LUAD cell proliferation. Additionally, the expression of NEDD4L is regulated by EGFR signaling.
JOURNAL OF TRANSLATIONAL MEDICINE
(2022)
Article
Clinical Neurology
Jeffrey Traylor, Hadley E. Sheppard, Visweswaran Ravikumar, Jonathan Breshears, Shaan M. Raza, Charles Y. Lin, Shreyaskumar R. Patel, Franco DeMonte
Summary: Through computational drug repositioning, researchers identified cytarabine and tretinoin as potential treatments for chordoma. Cytarabine demonstrated a concentration-dependent cytotoxic effect on human chordoma cells, while the effectiveness of tretinoin appeared to be cell line specific. Further evaluation of these compounds in additional human chordoma cell lines and animal models is recommended based on the findings.
Article
Oncology
Eddy S. Yang, Amin H. Nassar, Elio Adib, Opeyemi A. Jegede, Sarah Abou Alaiwi, Deborah L. Della Manna, David A. Braun, Mahsa Zarei, Heng Du, Sumanta K. Pal, Gurudatta Naik, Guru P. Sonpavde
Summary: The study investigated the relationship between gene expression and treatment benefit of Everolimus in metastatic renal cell carcinoma patients. Specific gene signatures were identified that could potentially predict the response to Everolimus monotherapy or combination therapy with a vascular disrupting agent. Further validation of these gene signatures is needed to determine their clinical utility in patient selection.
MOLECULAR CANCER THERAPEUTICS
(2021)
Review
Pharmacology & Pharmacy
Shota Yamamoto, Nobuaki Egashira
Summary: CIPN is a severe adverse effect observed in most patients treated with neurotoxic anticancer drugs, with no available therapeutic options for prevention. Understanding the specific characteristics of CIPN induced by different chemotherapeutic drugs is crucial, as well as focusing on drug repositioning studies and developing preventive strategies.
FRONTIERS IN PHARMACOLOGY
(2021)
Review
Cardiac & Cardiovascular Systems
Krishnan Warrior, Daniel F. Dilling
Summary: Lymphangioleiomyomatosis (LAM) is a rare cystic lung disease with respiratory symptoms and extra-thoracic manifestations. Lung transplantation can improve the life quality of LAM patients with end-stage lung disease, but there are unique considerations and complications associated with LAM. This review provides an overview of evaluation, management, and outcomes for LAM patients undergoing lung transplantation.
JOURNAL OF HEART AND LUNG TRANSPLANTATION
(2023)
Article
Chemistry, Organic
Scott W. Niman, Roberta Buono, David A. . Fruman, Christopher D. Vanderwal
Summary: We designed and executed a rapid synthesis of a complex analogue of the immunosuppressive natural product brasilicardin A using our recently developed MHAT-initiated radical bicyclization. The synthesis delivered the targeted analogue in 17 steps in the longest linear sequence. However, the analogue showed no observable immunosuppressive activity, highlighting the importance of the structural and stereochemical elements of the natural core scaffold.